Pioneering. Innovative. Insightful.
Mitomics is actively seeking partners who share our vision of improving clinical insight and therapeutic decisions. Because our Mitomic Tests can be developed on a number of different platforms, we're able to form strategic alliances with a range of potential partners from any point in the development or commercialization paths. With our comprehensive intellectual property estate around mitochondrial DNA (mtDNA), we're uniquely positioned to leverage the sensitivity, low cost and highly automated processing advantages of mtDNA molecular diagnostic tests over other forms of nuclear DNA and RNA tests.
Our products are multi-dimensional and are applicable to diverse industries - from pharmaceutical and diagnostic companies for our Prostate Core Mitomic Test™ to consumer and packaged goods manufacturers for our Skin Physical and Skin Care Mitomic Tests.
Our Mitomic Technology™ and library of proprietary mitochondrial associated molecules have the potential to extend beyond the clinical diagnostic market and into the development and commercialization of:
- Broad applications in diagnostic imaging through proprietary mitochondrial molecules
- Drug discoveries by highlighting currently unknown pathways through the use of our novel, mtDNA-based molecules, as well as pathways that avoid drug-induced mitochondrial toxicity
- Patient stratifications based on genetic predisposition, tumor aggression or expected therapy response, with expanded opportunities to regularly monitor those patients and their outcomes
What We Look For
When evaluating whether a potential partner is a strategic fit with our business model, we assess the following criteria:
- Global reach
- Corporate strategy
- Market position
- Alliance track record
- Product development effectiveness
To discuss alliance opportunities, please complete the form below or contact:
Robert J. Poulter
President & CEO
290 Munro Street, Suite 1000
Thunder Bay, Ontario